{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:16:54Z","timestamp":1794352614616,"version":"4.9.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105519","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:12:48Z","timestamp":1785942768000},"page":"105519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Urinary biomarkers for cancer diagnosis and surveillance: From analytical promise to clinical utility"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7416-1890","authenticated-orcid":false,"given":"Tingyin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105519_bib1","series-title":"Microhematuria: AUA\/SUFU guideline (2020, amended 2025)","article-title":"Female Pelvic Medicine & Urogenital Reconstruction","author":"American Urological Association\/Society of Urodynamics","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105519_bib2","series-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline (published 2016, amended 2020 and 2024)","author":"American Urological Association\/Society of Urologic Oncology","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105519_bib3","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MOU.0000000000001308","article-title":"Blood- and urine-based biomarkers for the detection of clinically significant prostate cancer: a contemporary review","volume":"35","author":"Assani","year":"2025","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"10.1016\/j.critrevonc.2026.105519_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105519_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-1354-2_1","article-title":"Urinary biomarkers in tumors: an overview","volume":"2292","author":"Cimmino","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2026.105519_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100310","article-title":"Liquid biopsy: current advancements in clinical practice for bladder cancer","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105519_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105519_bib10","series-title":"EAU guidelines on non-muscle-invasive bladder cancer","author":"European Association of Urology","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105519_bib11","series-title":"EAU guidelines on prostate cancer: diagnostic evaluation","author":"European Association of Urology","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105519_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib13","series-title":"Premarket approval P100033: PROGENSA PCA3 assay","author":"Food and Drug Administration","year":"2026"},{"key":"10.1016\/j.critrevonc.2026.105519_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1559-0275-10-13","article-title":"Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges","volume":"10","author":"F\u00fcz\u00e9ry","year":"2013","journal-title":"Clin. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105519_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MOU.0000000000001293","article-title":"Cost-effectiveness of serum, urine, and tissue-based prostate cancer biomarkers","volume":"35","author":"Gupta","year":"2025","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib16","doi-asserted-by":"crossref","first-page":"603.e1","DOI":"10.1016\/j.urolonc.2020.01.007","article-title":"A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade","volume":"38","author":"Hermanns","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib17","article-title":"Combination of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder cancer","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jnci\/djz112","article-title":"Temporal stability and prognostic biomarker potential of the prostate cancer urine miRNA transcriptome","volume":"112","author":"Jeon","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105519_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/biom13060932","article-title":"Protein biomarker discovery studies on urinary small extracellular vesicle fractions separated with UF-SEC for the first diagnosis and detection of recurrence in bladder cancer patients","volume":"13","author":"Jordaens","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2026.105519_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12014-024-09462-z","article-title":"Recent progress in mass spectrometry-based urinary proteomics","volume":"21","author":"Joshi","year":"2024","journal-title":"Clin. Proteom."},{"key":"10.1016\/j.critrevonc.2026.105519_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11306-018-1418-9","article-title":"Comparative analysis of creatinine and osmolality as urine normalization strategies in targeted metabolomics","volume":"14","author":"Khamis","year":"2018","journal-title":"Metabolomics"},{"key":"10.1016\/j.critrevonc.2026.105519_bib22","article-title":"Prostate cancer statistics, 2025","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105519_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.urolonc.2024.03.006","article-title":"Urinary extracellular vesicles-encapsulated miRNA signatures: a new paradigm for urinary bladder cancer diagnosis and classification","volume":"42","author":"Kural","year":"2024","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib25","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1038\/s41598-020-60616-z","article-title":"Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105519_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Lenis","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.euo.2024.09.011","article-title":"Clinical implementation of urinary biomarkers for surveillance of non-muscle-invasive bladder cancer: considerations from the European Association of Urology NMIBC Guideline Panel","volume":"8","author":"Liedberg","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib28","first-page":"4165","article-title":"Circulating miRNAs act as diagnostic biomarkers for bladder cancer in urine","volume":"22","author":"Lin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105519_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737159.2025.2565273","article-title":"Circulating tumor DNA and urinary tumor DNA: useful biomarkers for bladder cancer detection","volume":"25","author":"Lin","year":"2025","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"10.1016\/j.critrevonc.2026.105519_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/JU.0000000000003991","article-title":"A multicenter prospective randomized controlled trial comparing Cxbladder Triage to cystoscopy in patients with microhematuria: the Safe Testing of Risk for Asymptomatic Microhematuria trial","volume":"212","author":"Lotan","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","article-title":"Urine biomarkers in bladder cancer\u2014current status and future perspectives","volume":"20","author":"Maas","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib32","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/ijms20040821","article-title":"Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles","volume":"20","author":"Oeyen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105519_bib33","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"key":"10.1016\/j.critrevonc.2026.105519_bib34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/metabo11040199","article-title":"Discovery of volatile biomarkers for bladder cancer detection and staging through urine metabolomics","volume":"11","author":"Pinto","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.critrevonc.2026.105519_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.urolonc.2025.07.034","article-title":"Liquid biopsy testing in urological cancers: focus on urine","volume":"43","author":"Pisapia","year":"2025","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104699","article-title":"The impact of urine biomarkers for prostate cancer detection\u2014a systematic state-of-the-art review","volume":"210","author":"Plas","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","article-title":"Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer","volume":"28","author":"Robinson","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.critrevonc.2026.105519_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2026.01.035","article-title":"Diagnostic performance of urinary biomarker tests in detecting bladder cancer: a systematic review, meta-analysis, and network meta-analysis","author":"Siguencia","year":"2026","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105519_bib39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: a systematic review and meta-analysis","volume":"10","author":"Silva-Ferreira","year":"2024","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.critrevonc.2026.105519_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ctrv.2018.05.012","article-title":"Novel urinary biomarkers for the detection of bladder cancer: a systematic review","volume":"69","author":"Tan","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105519_bib41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: a review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JU.0000000000004421","article-title":"Clinical validation of MyProstateScore 2.0 testing using first-catch, non-digital rectal examination urine","volume":"213","author":"Tosoian","year":"2025","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib44","first-page":"149","article-title":"PCA3 and TMPRSS2:ERG urine level as diagnostic biomarker of prostate cancer","volume":"15","author":"Warli","year":"2023","journal-title":"Res. Rep. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1590\/s1677-5538.ibju.2021.99.02","article-title":"Proteomic research and diagnosis in bladder cancer: state-of-the-art review","volume":"47","author":"Wilson","year":"2021","journal-title":"Int. Braz. J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105519_bib46","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/pros.24229","article-title":"Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis","volume":"81","author":"Yu","year":"2021","journal-title":"Prostate"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:06:34Z","timestamp":1793088394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":46,"alternative-id":["S1040842826004063"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105519","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary biomarkers for cancer diagnosis and surveillance: From analytical promise to clinical utility","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105519","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105519"}}